Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757964 | 0.94 | MCHR1 (0.38) | EGLN1ADRA1DADRA1AADRA1BMCHR1 | |
| SCHEMBL5844743 | 0.89 | KMT2A (0.38) | ROCK2ADRA1DADRA1AADRA1BMCHR1 | |
| SCHEMBL5846949 | 0.87 | PDE10A (0.39) | ROCK2MCHR1HDAC8HDAC6GPR119 | |
| SCHEMBL5790113 | 0.86 | LMNA (0.40) | EGLN1ROCK2MCHR1HDAC8HDAC6 | |
| SCHEMBL5763136 | 0.85 | MCHR1 (0.47) | ROCK2MCHR1GPR119 | |
| SCHEMBL5847052 | 0.85 | P2RY1 (0.40) | ROCK2MCHR1 | |
| SCHEMBL5845894 | 0.83 | KDM4E (0.41) | ROCK2MAPT | |
| SCHEMBL5804389 | 0.82 | MCHR1 (0.45) | ROCK2MCHR1 | |
| SCHEMBL5761872 | 0.82 | MCHR1 (0.50) | ROCK2MCHR1 | |
| SCHEMBL5822403 | 0.78 | EGLN1 (0.45) | EGLN1ADRA1DADRA1AADRA1BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101885-B2 | 1-(4-Bromo-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one; antagonists of the serotonin 5HT1B receptor; treating depression | PFIZER INC (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | OPRD1, HTR5A, PTGDR | EGLN1 1585/4885ROCK2 3762/4885ADRA1D 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.